

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM796172

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Midcap Financial Trust		03/08/2023	Trust: DELAWARE
RECEIVING PARTY DATA			
Name:	MEDEXUS PHARMACEUTICALS INC.		
Street Address:	35 Nixon Road		
Internal Address:	Unit 1		
City:	Bolton		
State/Country:	ONTARIO		
Postal Code:	L7E1K1		
Entity Type:	Corporation: CANADA		
Name:	Medexus Pharma Inc.		
Street Address:	251 LITTLE FALLS DRIVE		
City:	WILMINGTON		
State/Country:	DELAWARE		
Postal Code:	19808		
Entity Type:	Corporation: DELAWARE		
Name:	MI ACQUISITIONS, INC.,		
Street Address:	CORPORATION TRUST CENTER 1209 ORANGE ST		
City:	WILMINGTON		
State/Country:	DELAWARE		
Postal Code:	19801		
Entity Type:	Corporation: DELAWARE		
Name:	APTEVO BIOTHERAPEUTICS LLC,		
Street Address:	251 LITTLE FALLS DRIVE		
City:	WILMINGTON		
State/Country:	DELAWARE		
Postal Code:	19808		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 7			

CH \$190.00 4597459

Property Type	Number	Word Mark
Registration Number:	4597459	IXINITY
Registration Number:	4923507	IXPERIENCE
Registration Number:	4788624	IXINITY
Registration Number:	4672924	RASUVO
Serial Number:	88098763	MEDEXUS PHARMA
Registration Number:	5288489	P
Registration Number:	5288488	PEDIAPHARM

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 5123916177

Email: jray@munsch.com

Correspondent Name: James Ray

Address Line 1: 1717 W. Sixth Street

Address Line 2: Suite 250

Address Line 4: Austin, TEXAS 78703

ATTORNEY DOCKET NUMBER:	18803.8
NAME OF SUBMITTER:	James Ray
SIGNATURE:	/james ray/
DATE SIGNED:	03/21/2023

Total Attachments: 7

source=Medexus-BMO - Release of Security Interest in IP (Midcap Financial Trust)#page1.tif
source=Medexus-BMO - Release of Security Interest in IP (Midcap Financial Trust)#page2.tif
source=Medexus-BMO - Release of Security Interest in IP (Midcap Financial Trust)#page3.tif
source=Medexus-BMO - Release of Security Interest in IP (Midcap Financial Trust)#page4.tif
source=Medexus-BMO - Release of Security Interest in IP (Midcap Financial Trust)#page5.tif
source=Medexus-BMO - Release of Security Interest in IP (Midcap Financial Trust)#page6.tif
source=Medexus-BMO - Release of Security Interest in IP (Midcap Financial Trust)#page7.tif

**RELEASE OF SECURITY INTEREST
IN INTELLECTUAL PROPERTY (TERM LOAN)**

This Release of Security Interest in Intellectual Property (Term Loan), dated as of March 8, 2023, is made by **MIDCAP FINANCIAL TRUST**, a Delaware statutory trust, (“**Agent**”), in favor of **MEDEXUS PHARMACEUTICALS INC.**, a corporation validly existing under the Canada Business Corporations Act, **MEDEXUS PHARMA, INC.**, a Delaware corporation, **MI ACQUISITIONS, INC.**, a Delaware corporation, **APTEVO BIOTHERAPEUTICS LLC**, a Delaware limited liability company (collectively, the “**Grantors**” and each, a “**Grantor**”):

WHEREAS, pursuant to that certain Intellectual Property Security Agreement, dated as of February 28, 2020 (as may have been further amended, modified, restated, replaced or supplemented from time to time, the “**IP Security Agreement**”; capitalized terms used herein have the definition provided for in the IP Security Agreement), recorded with the United States Patent and Trademark Office on March 6, 2020 at Reel/Frame No. 6884-0695 (Trademarks) and on March 6, 2020 at Reel/Frame No. 052039/0633 (Patents), each Grantor granted to Agent, on behalf of the Lenders, a security interest in and to all of its right, title and interest in all of such Grantor’s intellectual property, including those listed on Exhibit A through D thereto;

WHEREAS, the Grantors have requested that Agent release its security interest in and to the patent assets as more particularly described on Schedule A attached hereto (the “**Released Patents**”).

WHEREAS, the Grantors have requested that Agent release its security interest in and to the trademark assets as more particularly described on Schedule B attached hereto (the “**Released Trademarks**”).

WHEREAS, the Grantors have requested that Agent release its security interest in and to the various intellectual property assets set forth in Sections (a) through (j) of the IP Security Agreement (together with the Released Patents and Released Trademarks, the “**Released IP Collateral**”).

NOW, THEREFORE, Agent, without recourse, representation or warranty and at Grantors’ sole cost and expense, hereby releases all of its right, title and interest in and to the Released IP Collateral.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, Agent has caused this Release of Security Interest in Intellectual Property to be duly executed and delivered by its duly authorized officer as of the date first written above.


AGENT:

MIDCAP FINANCIAL TRUST

as Agent

By: Apollo Capital Management, L.P.,
its investment manager

By: Apollo Capital Management GP, LLC,
its general partner

By: 
Name: Maurice Amsellem
Title: Authorized Signatory

Schedule A

Patents

EXHIBIT B

Patents

Method of producing biologically active vitamin K dependent proteins by recombinant methods							
Aptevo Reference: APVO.40900							
Country	Application Number & file date	Publication/ WO Number	Patent Number	Issue Date	Expiration Date	Assignee	Application Status
US	15/875,373 1/19/2018	2019/003210 1				Aptevo Bio and the University of North Carolina at Chapel Hill	Pending

METHOD OF PRODUCING RECOMBINANT VITAMIN K DEPENDENT PROTEINS							
Aptevo Reference: APVO.40901							
Country	Application Number & file date	Publication/WO Number	Patent Number	Issue Date	Expiration Date	Assignee	Application Status
US	14/475,881 9/03/2014	2014/0369994	9,587,008	3/07/2017	10/28/2030	Aptevo Bio	Granted

STABILIZED FACTOR IX FORMULATIONS CONTAINING TREHALOSE							
Aptevo Reference: APVO.40902							
Country	Application Number & file date	Publication/WO Number	Patent Number	Issue Date	Expiration Date	Assignee	Application Status
US	16/028,736 7/9/2018	2019/0167 797				Aptevo Bio	Pending

RECOMBINANT VITAMIN K DEPENDENT PROTEINS WITH HIGH SIALIC ACID CONTENT AND METHODS OF PREPARING SAME							
Aptevo Reference: APVO.40903							
Country	Application Number & file date	Publication/WO Number	Patent Number	Issue Date	Expiration Date	Assignee	Application Status
US	16/409,385 5/10/2019	2019/0264188				Aptevo Bio	Pending


Schedule B

Trademarks

EXHIBIT C



Trademarks

Aptevo Bio

Mark	Country	Class Goods	Appl. No	Appl. Date	Reg No	Reg Date
IXINITY	US	(005 - INTERNATIONAL) Pharmaceutical preparations for the treatment of hemophilia	85/220,714	01/19/2011	4,597,459	09/02/2014
IXPERIENCE	US	(044 - INTERNATIONAL) Medical consultation; patient assistance programs, namely, providing information to patients in the field of administering medications, patient counseling regarding hemophilia, counseling services relating to hemophilia management, providing patient information relating to the therapeutic properties of pharmaceuticals, and providing online information relating to therapeutic properties of pharmaceuticals; discount drug plan, namely, patient assistance programs to provide drugs at a discounted rate to low-income patients	86/322,313	06/27/2014	4,923,507	03/22/2016
 IXINITY	US	(005 - INTERNATIONAL) Pharmaceutical preparations for the	86/322,323	06/27/2014	4,788,624	08/11/2015

Mark	Country	Class Goods	Appl. No	Appl. Date	Reg No	Reg Date
		treatment of hemophilia				

Medexus

Loan Party	Trademark	Country	Application No.	Registration No.
Medexus Pharma, Inc. (f/k/a medac pharma, Inc.)	RASUVO	U.S.	86152434	4672924
Medexus Inc.		U.S.	88098763	n/a
Medexus Pharmaceuticals Inc.		U.S.	86584173	5288489
Medexus Pharmaceuticals Inc.	PEDIAPHARM	U.S.	86584159	5288488